中图分类号 R969.3；R956 文献标志码 A 文章编号 1001-0408(2025)11-1405-06

    DOI 10.6039/j.issn.1001-0408.2025.11.21

    ABSTRACT OBJECTIVE To evaluate the efficacy，safety and cost-effectiveness of serplulimab as a first-line treatment of smallcell lung cancer(SCLC)，and provide an evidence-based basis for drug selection in hospitals. METHODS Rapid health technology assessment was adopted；PubMed，Cochrane Library，Embase，CNKI，Wanfang，VIP and official websites of domestic and international health technology assessment agencies were systematically searched from the inception to Oct. 2024. Two reviewers independently screened the literature，assessed the quality of included studies and carried out the qualitative analysis according to the inclusion and exclusion criteria. RESULTS A total of 13 systematic reviews/meta-analyses and 9 economic studies were included，and the literature quality was generally good. In terms of effectiveness，compared with chemotherapy alone，serplulimab combined with chemotherapy significantly improved progression-free survival，overall survival，and objective response rate in patients with SCLC. In terms of safety ......